National Genomic Test Directory

panel for rare disease. The panels brought together clinicians, scientists, health economists, policy experts, public representatives and patient organisations. The panel developed a methodology to reflect the changing technology and consider the optimal testing for a clinical condition, rather than a specific gene, to ................
................